A Multifunctional Mesothelin Antibody-tagged Microparticle Targets Human Mesotheliomas

Journal of Histochemistry and Cytochemistry

Volumn 60, Issue 9, 2012, Pages 658-674

  Macura, Sherrill L ^a   Hillegass, Jedd M ^a   Steinbacher, Jeremy L ^a,c   MacPherson, Maximilian B ^a   Shukla, Arti ^a   Beuschel, Stacie L ^a   Perkins, Timothy N ^a   Butnor, Kelly J ^a   Lathrop, Melissa J ^b   Sayan, Mutlay ^a   Hekmatyar, Khan ^e   Taatjes, Douglas J ^a   Kauppinen, Risto A ^d   Landry, Christopher C ^a,c   Mossman, Brooke T ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b Department of Medicine ^*  (United States)

^c UNIVERSITY OF VERMONT   (United States)

^d UNIVERSITY OF GEORGIA   (United States)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

amorphous silica; malignant mesothelioma; mesothelin; targeted microparticle

Indexed keywords

ACID PREPARED MESOPOROUS SPHERE; BOVINE SERUM ALBUMIN; MESOTHELIN; MICROSPHERE; UNCLASSIFIED DRUG; DIFFERENTIATION ANTIGEN; DRUG CARRIER; FLUORESCENT DYE; GADOLINIUM; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MONOCLONAL ANTIBODY; SILICON DIOXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; DRUG TUMOR LEVEL; ENCAPSULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; KIDNEY; LIVER; MASS SPECTROMETRY; MEMBRANE MICROPARTICLE; MESOTHELIOMA; MOUSE; NONHUMAN; PERITONEUM LAVAGE; PRIORITY JOURNAL; RAT; SPLEEN; SYNTHESIS; URINE; ANIMAL; CATTLE; CHEMISTRY; DOG; IMMUNOLOGY; MESENTERY; METABOLISM; MOUSE MUTANT; MULTICELLULAR SPHEROID; PARTICLE SIZE; PERITONEUM TUMOR; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

BOVINAE; MUS; RATTUS; RODENTIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, DIFFERENTIATION; CATTLE; CELL LINE, TUMOR; DOGS; DRUG CARRIERS; FLUORESCENT DYES; GADOLINIUM; GPI-LINKED PROTEINS; HUMANS; MESENTERY; MESOTHELIOMA; MICE; MICE, SCID; PARTICLE SIZE; PERITONEAL NEOPLASMS; RATS; SERUM ALBUMIN, BOVINE; SILICON DIOXIDE; SPHEROIDS, CELLULAR; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84867681494     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155412452567     Document Type: Article

References (70)

1. Albelda SM.Gene therapy for lung cancer and mesothelioma.Chest. 1997;111:144S-149S.
2. Bast RC,Klug TL,St John E,Jenison E,Niloff JM,Lazarus H,Berkowitz RS,Leavitt T,Griffiths CT,Parker L, et al.A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.N Engl J Med. 1983;309:883-887.
3. Bielefeldt-Ohmann H,Fitzpatrick DR,Marzo AL,Jarnicki AG,Himbeck RP,Davis MR,Manning LS,Robinson BW.Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model.Cancer Immunol Immunother. 1994;39:347-359.
4. Blumen SR,Cheng K,Ramos-Nino ME,Taatjes DJ,Weiss DJ,Landry CC,Mossman BT.Unique uptake of acid-prepared mesoporous spheres by lung epithelial and mesothelioma cells.Am J Respir Cell Mol Biol. 2007;36:333-342.
5. Borm PJ,Kreyling W.Toxicological hazards of inhaled nanoparticles-potential implications for drug delivery.J Nanosci Nanotechnol. 2004;4:521-531.
6. Brooks EG,Trotman W,Wadsworth MP,Taatjes DJ,Evans MF,Ittleman FP,Callas PW,Esmon CT,Bovill EG.Valves of the deep venous system: an overlooked risk factor.Blood. 2009;114:1276-1279.
7. Chang K,Pastan I.Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.Proc Natl Acad Sci U S A. 1996;93:136-140.
8. Cheng K,Blumen SR,MacPherson MB,Steinbacher JL,Mossman BT,Landry CC.Enhanced uptake of porous silica microparticles by bifunctional surface modification with a targeting antibody and a biocompatible polymer.ACS Appl Mater Interfaces. 2010;2:2489-2495.
9. Cheng K,El-Boubbou K,Landry CC.Binding of HIV-1 gp120 glycoprotein to silica nanoparticles modified with CD4 glycoprotein and CD4 peptide fragments.ACS Appl Mater Interfaces. 2012;4:235-243.
10. Dickson MA,Hahn WC,Ino Y,Ronfard V,Wu JY,Weinberg RA,Louis DN,Li FP,Rheinwald JG.Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics.Mol Cell Biol. 2000;20:1436-1447.
11. Fennell DA,Rudd RM.Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development.Lancet Oncol. 2004;5:354-362.
12. GallisKWLandryCC. 2002. Mesoporous silicates and method of making same. US Patent No. 6,334,988.
13. Gotloib L,Shostak A.Endocytosis and transcytosis of albumin gold through mice peritoneal mesothelium.Kidney Int. 1995;47:1274-1284.
14. Grosso F,Scagliotti GV.Systemic treatment of malignant pleural mesothelioma.Future Oncol. 2012;8:293-305.
15. Gubbels JAA,Belisle J,Onda M,Rancourt C,Migneault M,Ho M,Bera TK,Connor J,Sathyanarayana BK,Lee B.Mesothelin-MUC 16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors.Mol Cancer. 2006;5:50.
16. Handy RD,Henry TB,Scown TM,Johnston BD,Tyler CR.Manufactured nanoparticles: their uptake and effects on fish-a mechanistic analysis.Ecotoxicology. 2008;17:396-409.
17. Hassan R,Bera T,Pastan I.Mesothelin: a new target for immunotherapy.Clin Cancer Res. 2004;10:3937-3942.
18. Hassan R,Broaddus VC,Wilson S,Liewehr DJ,Zhang J.Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.Clin Cancer Res. 2007;13:7166-7171.
19. Hassan R,Bullock S,Premkumar A,Kreitman RJ,Kindler H,Willingham MC,Pastan I.Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.Clin Cancer Res. 2007;13:5144-5149.
20. Hassan R,Cohen SJ,Phillips M,Pastan I,Sharon E,Kelly RJ,Schweizer C,Weil S,Laheru D.Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.Clin Cancer Res. 2010;16:6132-6138.
21. Hassan R,Ebel W,Routhier EL,Patel R,Kline JB,Zhang J,Chao Q,Jacob S,Turchin H,Gibbs L, et al.Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.Cancer Immun. 2007;7:20.
22. Hassan R,Ho M.Mesothelin targeted cancer immunotherapy.Eur J Cancer. 2008;44:46-53.
23. Hegmans JP,Hemmes A,Hammad H,Boon L,Hoogsteden HC,Lambrecht BN.Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses.Eur Respir J. 2006;27:1086-1095.
24. Hesdorffer ME,Chabot J,DeRosa C,Taub R.Peritoneal mesothelioma.Curr Treat Options Oncol. 2008;9:180-190.
25. Hesdorffer ME,Chabot JA,Keohan ML,Fountain K,Talbot S,Gabay M,Valentin C,Lee SM,Taub RN.Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma.Am J Clin Oncol. 2008;31:49-54.
26. Hillegass JM,Blumen SR,Cheng K,MacPherson MB,Alexeeva V,Lathrop SA,Beuschel SL,Steinbacher JL,Butnor KJ,Ramos-Niño ME.Increased efficacy of doxorubicin delivered in multifunctional microparticles for mesothelioma therapy.Int J Cancer. 2011;129:233-244.
27. Hillegass JM,Shukla A,Lathrop SA,MacPherson MB,Beuschel SL,Butnor KJ,Testa JR,Pass HI,Carbone M,Steele C, et al.Inflammation precedes the development of human malignant mesotheliomas in a SCID mouse xenograft model.Ann N Y Acad Sci. 2010;1203:7-14.
28. Ho M,Bera TK,Willingham MC,Onda M,Hassan R,FitzGerald D,Pastan I.Mesothelin expression in human lung cancer.Clin Cancer Res. 2007;13:1571-1575.
29. Ho M,Hassan R,Zhang J,Wang QC,Onda M,Bera T,Pastan I.Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.Clin Cancer Res. 2005;11:3814-3820.
30. Ho M,Onda M,Wang QC,Hassan R,Pastan I,Lively MO.Mesothelin is shed from tumor cells.Cancer Epidemiol Biomarkers Prev. 2006;15:1751.
31. Hudson SP,Padera RF,Langer R,Kohane DS.The biocompatibility of mesoporous silicates.Biomaterials. 2008;29:4045-4055.
32. John TA,Vogel SM,Tiruppathi C,Malik AB,Minshall RD.Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer.Am J Physiol Lung Cell Mol Physiol. 2003;284:L187-L196.
33. Kobayashi H,Man S,Graham CH,Kapitain SJ,Teicher BA,Kerbel RS.Acquired multicellular-mediated resistance to alkylating agents in cancer.Proc Natl Acad Sci U S A. 1993;90:3294-3298.
34. Kreitman RJ,Hassan R,Fitzgerald DJ,Pastan I.Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P.Clin Cancer Res. 2009;15:5274-5279.
35. Le DT,Brockstedt DG,Nir-Paz R,Hampl J,Mathur S,Nemunaitis J,Sterman DH,Hassan R,Lutz E,Moyer B, et al.A live-attenuated listeria vaccine (ANZ-100) and a live-attenuated listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.Clin Cancer Res. 2012;18:858-868.
36. Li SD,Howell SB.CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases.Mol Pharm. 2009;7:280-290.
37. Mantovani A,Allavena P,Sica A.Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression.Eur J Cancer. 2004;40:1660-1667.
38. Mantovani A,Schioppa T,Porta C,Allavena P,Sica A.Role of tumor-associated macrophages in tumor progression and invasion.Cancer Metastasis Rev. 2006;25:315-322.
39. Martin FJ,Melnik K,West T,Shapiro J,Cohen M,Boiarski AA,Ferrari M.Acute toxicity of intravenously administered microfabricated silicon dioxide drug delivery particles in mice: preliminary findings.Drugs R D. 2005;6:71-81.
40. Miettinen M,Sarlomo-Rikala M.Expression of calretinin, thrombomodulin, keratin 5, and mesothelin in lung carcinomas of different types: an immunohistochemical analysis of 596 tumors in comparison with epithelioid mesotheliomas of the pleura.Am J Surg Pathol. 2003;27:150-158.
41. Minshall RD,Tiruppathi C,Vogel SM,Niles WD,Gilchrist A,Hamm HE,Malik AB.Endothelial cell-surface gp60 activates vesicle formation and trafficking via Gi-coupled Src kinase signaling pathway.J Cell Biol. 2000;150:1057-1070.
42. Mirarabshahii P,Pillai K,Chua TC,Pourgholami MH,Morris DL.Diffuse malignant peritoneal mesothelioma-an update on treatment.Cancer Treat Rev. 2012;38:605-612.
43. Miselis NR,Wu ZJ,Van Rooijen N,Kane AB.Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma.Mol Cancer Ther. 2008;7:788-799.
44. Mossman BT,Bignon J,Corn M,Seaton A,Gee JB.Asbestos: scientific developments and implications for public policy.Science. 1990;247:294-301.
45. Nassivera T,Eklund AG,Landry CC.Size-exclusion chromatography of low-molecular-mass polymers using mesoporous silica.J Chromatogr A. 2002;973:97-101.
46. Oberdorster G,Maynard A,Donaldson K,Castranova V,Fitzpatrick J,Ausman K,Carter J,Karn B,Kreyling W,Lai D, et al.Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy.Part Fibre Toxicol. 2005;2:8.
47. Oberdorster G,Oberdorster E,Oberdorster J.Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles.Environ Health Perspect. 2005;113:823-839.
48. Pantarotto D,Briand JP,Prato M,Bianco A.Translocation of bioactive peptides across cell membranes by carbon nanotubes.Chem Commun (Camb). 2004;2004:16-17.
49. Pass HI,Stevens EJ,Oie H,Tsokos MG,Abati AD,Fetsch PA,Mew DJ,Pogrebniak HW,Matthews WJ.Characteristics of nine newly derived mesothelioma cell lines.Ann Thorac Surg. 1995;59:835-844.
50. Pastan I,Zhang Y.Modulating mesothelin shedding to improve therapy.Oncotarget. 2012;3:114-115.
51. Reale FR,Griffin TW,Compton JM,Graham S,Townes PL,Bogden A.Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model.Cancer Res. 1987;47:3199-3205.
52. Richards WG,Zellos L,Bueno R,Jaklitsch MT,Janne PA,Chirieac LR,Yeap BY,Dekkers RJ,Hartigan PM,Capalbo L, et al.Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.J Clin Oncol. 2006;24:1561-1567.
53. Robinson BW,Creaney J,Lake R,Nowak A,Musk AW,de Klerk N,Winzell P,Hellstrom KE,Hellstrom I.Mesothelin-family proteins and diagnosis of mesothelioma.Lancet. 2003;362:1612-1616.
54. Robinson BW,Creaney J,Lake R,Nowak A,Musk AW,de Klerk N,Winzell P,Hellstrom KE,Hellstrom I.Soluble mesothelin-related protein-a blood test for mesothelioma.Lung Cancer. 2005;49:S109-S111.
55. Rump A,Morikawa Y,Tanaka M,Minami S,Umesaki N,Takeuchi M,Miyajima A.Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion.J Biol Chem. 2004;279:9190-9198.
56. Schafer V,von Briesen H,Rubsamen-Waigmann H,Steffan AM,Royer C,Kreuter J.Phagocytosis and degradation of human serum albumin microspheres and nanoparticles in human macrophages.J Microencapsul. 1994;11:261-269.
57. Scherpereel A,Grigoriu B,Conti M,Gey T,Gregoire M,Copin MC,Devos P,Chahine B,Porte H,Lassalle P.Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.Am J Respir Crit Care Med. 2006;173:1155-1160.
58. Scholler N,Fu N,Yang Y,Ye Z,Goodman GE,Hellstrom KE,Hellstrom I.Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma.Proc Natl Acad Sci U S A. 1999;96:11531-11536.
59. Shukla A,Bosenberg MW,MacPherson MB,Butnor KJ,Heintz NH,Pass HI,Carbone M,Testa JR,Mossman BT.Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis.Am J Pathol. 2009;175:2197-2206.
60. Steinbacher JL,Lathrop SA,Cheng K,Hillegass JM,Butnor KJ,Kauppinen RA,Mossman BT,Landry CC.Gd-labeled microparticles in MRI: in vivo imaging of microparticles after intraperitoneal injection.Small. 2010;6:2678-2682.
61. Sugarbaker P,Yan T,Stuart O,Yoo D.Comprehensive management of diffuse malignant peritoneal mesothelioma.Eur J Surg Oncol. 2006;32:686-691.
62. Van der Speeten K,Stuart OA,Mahteme H,Sugarbaker PH.A pharmacologic analysis of intraoperative intracavitary cancer chemotherapy with doxorubicin.Cancer Chemother Pharmacol. 2009;63:799-805.
63. Van der Speeten K,Stuart OA,Sugarbaker PH.Pharmacokinetics and pharmacodynamics of perioperative cancer chemotherapy in peritoneal surface malignancy.Cancer J. 2009;15:216-224.
64. van Ruth S,Baas P,Haas RL,Rutgers EJ,Verwaal VJ,Zoetmulder FA.Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma.Ann Surg Oncol. 2003;10:176-182.
65. van Ruth S,van Tellingen O,Korse CM,Verwaal VJ,Zoetmulder FA.Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma.Anticancer Drugs. 2003;14:57-65.
66. Vogel SM,Minshall RD,Pilipovic M,Tiruppathi C,Malik AB.Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein.Am J Physiol Lung Cell Mol Physiol. 2001;281:L1512-L1522.
67. Warheit DB.Inhaled amorphous silica particulates: what do we know about their toxicological profiles?.J Environ Pathol Toxicol Oncol. 2001;20:133-141.
68. Xia T,Kovochich M,Brant J,Hotze M,Sempf J,Oberley T,Sioutas C,Yeh JI,Wiesner MR,Nel AE.Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm.Nano Lett. 2006;6:1794-1807.
69. Zauderer MG,Krug LM.The evolution of multimodality therapy for malignant pleural mesothelioma.Curr Treat Options Oncol. 2011;12:163-172.
70. Zhang Y,Chertov O,Zhang J,Hassan R,Pastan I.Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.Cancer Res. 2011;71:5915-5922.